icad

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Earnings

News

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

BPTS

ICAD

LIXT

MASI

MICS

NMTR

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday.

The Dow traded up 1.09% to 34,961.65 while the NASDAQ rose 0.91% to 14,374.77. The S&amp;P 500, also rose, gaining, 0.77% to 4,557.83.

Nasdaq Gains Over 100 Points; Lockheed Martin Profit Tops Expectations

Small Cap

Movers

ABOS

ADES

APLS

APVO

ARDS

ATRO

ATUS

AWIN

EOSE

Euda Health Holdings Limited - Ordinary Shares

EUDA

EXPI

FREY

FWBI

GRRR

HCTI

HYPR

INOD

IRNT

ISUN

LINK

MBWM

MNMD

NOVN

PACW

PIRS

QBTS

RVYL

SCHW

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SNAX

UTME

Gainers


	Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.


Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 300 points on Tuesday.

The Dow traded up 1% to 34,932.08 while the NASDAQ rose 0.34% to 14,293.55. The S&amp;P 500, also rose, gaining, 0.46% to 4,543.70.

Dow Jumps Over 300 Points; Morgan Stanley Posts Upbeat Earnings

icad Inc

Icade

Press Releases

iCAD Reports Financial Results for Third Quarter Ended September 30, 2024

Health Care

iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024

CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024

Economics

SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations

iCAD Pre-Announces Estimated Q4 2024 Revenue

iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025

Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025

iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America

iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025

iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Claritev Corporation Class A Common Stock

Claritev

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

LifeMD

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

VSee Health

Waystar Holding

Lake Street

JMP Securities

Oppenheimer

BTIG

Comments

icad

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga